231 related articles for article (PubMed ID: 16240686)
21. Further evidence for low-dose combinations in patients with left ventricular hypertrophy.
Dahlöf B
J Hum Hypertens; 2005 Jun; 19 Suppl 1():S9-14. PubMed ID: 16075032
[TBL] [Abstract][Full Text] [Related]
22. Tissue velocity echocardiography shows early improvement in diastolic function with irbesartan and atenolol therapy in patients with hypertensive left ventricular hypertrophy. Results form the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA).
Müller-Brunotte R; Kahan T; Malmqvist K; Ring M; Edner M
Am J Hypertens; 2006 Sep; 19(9):927-36. PubMed ID: 16942935
[TBL] [Abstract][Full Text] [Related]
23. Risk reduction after regression of echocardiographic left ventricular hypertrophy in hypertension: a meta-analysis.
Pierdomenico SD; Cuccurullo F
Am J Hypertens; 2010 Aug; 23(8):876-81. PubMed ID: 20414193
[TBL] [Abstract][Full Text] [Related]
24. Regression of left ventricular hypertrophy in children with antihypertensive therapy.
Ramaswamy P; Lytrivi ID; Paul C; Golden M; Kupferman JC
Pediatr Nephrol; 2007 Jan; 22(1):141-3. PubMed ID: 16955278
[TBL] [Abstract][Full Text] [Related]
25. Relation of QT interval and QT dispersion to regression of echocardiographic and electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan Intervention For Endpoint Reduction (LIFE) study.
Oikarinen L; Nieminen MS; Toivonen L; Viitasalo M; Wachtell K; Papademetriou V; Jern S; Dahlöf B; Devereux RB; Okin PM;
Am Heart J; 2003 May; 145(5):919-25. PubMed ID: 12766755
[TBL] [Abstract][Full Text] [Related]
26. Complete reversal of hypertensive cardiomyopathy after initiating combined antihypertensive therapy.
Holl MJ; van de Poll SW; Michels M
BMJ Case Rep; 2016 Apr; 2016():. PubMed ID: 27060071
[TBL] [Abstract][Full Text] [Related]
27. Ventricular hypertrophy and hypertension: prognostic elements and implications for management.
Krauser DG; Devereux RB
Herz; 2006 Jun; 31(4):305-16. PubMed ID: 16810470
[TBL] [Abstract][Full Text] [Related]
28. Effects of antihypertensive agents on the left ventricle: clinical implications.
Díez J; González A; López B; Ravassa S; Fortuño MA
Am J Cardiovasc Drugs; 2001; 1(4):263-79. PubMed ID: 14728026
[TBL] [Abstract][Full Text] [Related]
29. Clinical impact of 'in-treatment' wall motion abnormalities in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Cicala S; de Simone G; Wachtell K; Gerdts E; Boman K; Nieminen MS; Dahlöf B; Devereux RB
J Hypertens; 2008 Apr; 26(4):806-12. PubMed ID: 18327092
[TBL] [Abstract][Full Text] [Related]
30. [Significance of left ventricular hypertrophy in primary hypertension and therapeutic modification by antihypertensive drugs].
Schiemann AL; Stimpel M
Praxis (Bern 1994); 1997 Jul; 86(27-28):1101-6. PubMed ID: 9324718
[TBL] [Abstract][Full Text] [Related]
31. Hypertensive heart disease.
Diamond JA; Phillips RA
Hypertens Res; 2005 Mar; 28(3):191-202. PubMed ID: 16097361
[TBL] [Abstract][Full Text] [Related]
32. Greater regression of electrocardiographic left ventricular hypertrophy during hydrochlorothiazide therapy in hypertensive patients.
Okin PM; Hille DA; Kjeldsen SE; Lindholm LH; Edelman JM; Dahlöf B; Devereux RB
Am J Hypertens; 2010 Jul; 23(7):786-93. PubMed ID: 20395941
[TBL] [Abstract][Full Text] [Related]
33. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
Palmieri V; Devereux RB
Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
[TBL] [Abstract][Full Text] [Related]
34. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events.
Okin PM; Devereux RB; Jern S; Kjeldsen SE; Julius S; Nieminen MS; Snapinn S; Harris KE; Aurup P; Edelman JM; Wedel H; Lindholm LH; Dahlöf B;
JAMA; 2004 Nov; 292(19):2343-9. PubMed ID: 15547161
[TBL] [Abstract][Full Text] [Related]
35. Left ventricular midwall function improves with antihypertensive therapy and regression of left ventricular hypertrophy in patients with asymptomatic hypertension.
Schussheim AE; Diamond JA; Phillips RA
Am J Cardiol; 2001 Jan; 87(1):61-5. PubMed ID: 11137835
[TBL] [Abstract][Full Text] [Related]
36. [Left ventricular hypertrophy in paediatric predialysis children and treatment--induced regression of left ventricular mass].
Borzych D; Zurowska A; Bałasz I; Sabiniewicz R; Ereciński J
Wiad Lek; 2005; 58 Suppl 1():55-7. PubMed ID: 16060086
[TBL] [Abstract][Full Text] [Related]
37. Left ventricular function and regression of left ventricular hypertrophy in essential hypertension.
Clement DL; De Buyzere M; Duprez D
Am J Hypertens; 1993 Mar; 6(3 Pt 2):14S-19S. PubMed ID: 8466720
[TBL] [Abstract][Full Text] [Related]
38. Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial.
Gerdts E; Wachtell K; Omvik P; Otterstad JE; Oikarinen L; Boman K; Dahlöf B; Devereux RB
Hypertension; 2007 Feb; 49(2):311-6. PubMed ID: 17178978
[TBL] [Abstract][Full Text] [Related]
39. Treatment of left ventricular hypertrophy in hypertensive patients.
Tamargo J; Delpón E; Valenzuela C
Eur Heart J; 1993 Nov; 14 Suppl J():102-6. PubMed ID: 8281952
[TBL] [Abstract][Full Text] [Related]
40. Effect of diuretic therapy on hypertensive left ventricular hypertrophy.
Massie BM
Eur Heart J; 1992 Dec; 13 Suppl G():53-60. PubMed ID: 1486907
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
